Plné znění - 80/2017 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2017 - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

80/2017 Sb. m. s.

Sdělení

INFORMACE

80

XXXXXXX

Xxxxxxxxxxxx zahraničních věcí,

kterým xx xxxx a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. x x. 46/2008 Xx. x. x.

 

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 28. xxxxxxxxx 2016 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X (Xxxxxx zakázaných xxxxx a xxxxx xxxxxxx xxx xxx 2017 - Mezinárodní xxxxxxxx) Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx¹⁾.

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx a prezident xxxxxxxxx xxxxxxxx listinu x přijetí změn Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx X xxxxxxxxx x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2017 x xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 30. xxxxx 2017.

Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I xxxxxx xx 1. xxxxx 2016, vyhlášené xxx č. 26/2017 Sb. m. s.

Xxxxxxxx xxxxx Přílohy X x xxxx xxxxxxx do českého xxxxxx xx xxxxxxxxx xxxxxxxx.

XXXXXXX ANTIDOPINGOVÝ XXXXX

XXXXXX XXXXXXXXXX XXXXX A XXXXX XXXXXXX XXX XXX 2017

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx xxxxxxxxx XXXX x xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx a xxxxxxxxxxxx verzí bude xxxxxxxxxxx anglická xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2017 

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2017

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. ledna 2017

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek xx xxxxxx S1, X2, X4.4, X4.5 x S6(a) x Xxxxxxxxxx metod X1, X2 x X3.

XXXXX X METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

XXXXXXXX XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxxx xxxxxx xxxxx, xxxxx xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (např. xxxxxx x preklinickém xxxx xxxxxxxxx stadiu xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* AAS, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion);

bolandiol (estr-4-en-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);

methylnortestosteron (17ß-hydroxy-17α-methylestr-4-en-3-on);

methyItestosteron;

metribolon (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx látky s xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

x. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxxxx-3xx); 

xxxxxxxxx (19-xxxxxxxxxxxxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (dehydroepiandrosteron, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx pouze xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx modulátory xxxxxxxxxxxxx receptorů (XXXX, xxxx. xxxxxxx a xxxxxxx); xxxxxxx; zeranol x xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " se vztahuje x látce, xxxxxx xxxx xxxxxxxx přirozeně xxxxxxxxx.

X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými účinky xxxx zakázány:

1. Agonisté xxxxxxxxxxxxxxxxx receptoru:

1.1 Látky xxxxxxxxxxx xxxxxxxxxxx (XXX) xxxxxx xxxx.

xxxxxxxxxxxx (dEPO);

erytropoetinů (XXX);

XXX-Xx;

XXX-xxxxxxxxxxx peptidů (XXX), xxxx. XXXX 530 x xxxxxxxxxxx;

xxxxxxxxxx GATA, xxxx. X-11706;

xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX);

xxxxxxxxxx xxxxxxxxxxxxxxxx růstového xxxxxxx beta (XXX-xxxx), xxxx. xxxxxxxxxxx, xxxxxxxxxxxx;

1.2 Xxxxxxxx xxxxxxxxxxxxxxxxxx XXX xxxxxxxxx, např.

ARA-290;

asialo XXX;

xxxxxxxxxxxxx XXX;

2. Xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx, xxxxxxxxxx x roxadustat (XX-4592); x xxxxxxxxxx XXX, xxxx. xxxxx x xxxxx.

3. Xxxxxxxxxxxxxxxxxx (CG) x luteinizační xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, gonadorelin a xxxxxxxxxxx, x xxxx.

4. Xxxxxxxxxxxxxx x jejich xxxxxxxxxx faktory, např. xxxxxxxxxxxx.

5. Xxxxxxx xxxxxx (XX) a xxxx xxxxxxxxxx xxxxxxx xxxxxx: xxxxxxx uvolňujícího xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1295, sermorelinu a xxxxxxxxxxxx; sekretagogů xxxxxxxxx xxxxxxx (GHS), xxxx. xxxxxxxx a xxxxxxx xxxxxxxx, xxxx. anamorelinu x xxxxxxxxxxx; uvolňujících xxxxxxx růstového hormonu (XXXX), např. alexamorelinu, XXXX-6, xxxxxxxxxx a xxxxxxxxxxxx (XXXX- 2).

Kromě xxxx xxxx zakázány xxxxxxxxxxx xxxxxxx faktory:

Fibroblastové xxxxxxx xxxxxxx (XXXx); xxxxxxxxxxxx xxxxxxx xxxxxx (XXX); insulinu xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x jeho xxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxx (XXX); xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX); xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (VEGF), xxxxxx xxxx xxxxxxxxx xxxx růstové xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx zásobení, využití xxxxxxx, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx selektivní x xxxxxxxxxxxx xxxx2- xxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, xxxx zakázáni.

Zahrnují (xxx ne s xxxxxxxx pouze xx xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; xxxxxxxxxxx; xxxxxxxxxx; prokaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx, xxxxxxxxxxx 800 xxxxxxxxxx xx xxxxxxx 12 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin.

Přítomnost xxxxxxxxxxx v moči x xxxxxxxxxxx vyšší xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 ng/ml nebude xxxxxxxxxx za zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx užíváním xxxxxxxxxxxx dávky (v xxxxxxxx) xxxxx, než xxxx xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx hormonové x xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, zahrnující:

Aminoglutethimid;

anastrozol;

androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx,

xxx xx x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx estrogenových receptorů (XXXX), zahrnující:

Raloxifen;

tamoxifen;

toremifen, xxx ne x xxxxxxxx xxxxx na xx.

3. Ostatní antiestrogenní xxxxx zahrnující:

Cyklofenil; xxxxxxxxxxx x klomifen, xxx xx x xxxxxxxx xxxxx na ně.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx ne

s xxxxxxxx xxxxx na xx.

5. Metaboiické xxxxxxxxxx:

5.1 Xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. XX 1516;

5.2 Xxxxxxxx x xxxxxxxx insulinů;

5.3 Xxxxxxxxx;

5.4 Trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx xxxx xxxxxxxx, xxxxxx jako xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou a xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx, xxxxxxxxxxxxxxx (např. xxxxxxxx, xxxxxxxxxx podání albuminu, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx), probenecid, xxx xx x xxxxxxxx xxxxx xx ně.

• Acetazolamid, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx, xxxxxxxxx a xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx xxx zubní xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx

xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx maskovací xxxxxx, xxxx považováno xx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx x té, xxxxx xxx byla xxxxxxx xx xxxxxxxxxx nebo xxxxx maskovací xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxx nebo znovuzavedení xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx podobných xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx náhražky xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (RSR13), xxx xx x xxxxxxxx xxxxx xx xx. Inhalační xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x krví xxxx s krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx způsoby.

M2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx o Xxxxxx, xx účelem xxxxxxx xxxxxxxxx a xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx kontrole. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (např. xxxxxxxxxx) xxxx, xxx xx x omezením xxxxx xx xx.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx než 50 xx xx 6 hodin kromě xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, chirurgických xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.

X3. GENOVÝ XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX PŘI XXXXXXX

Xxxxx xxxxxxxxx S0 až X5 a X1 xx X3 uvedených xxxx

xxxx Xxx Soutěži xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx optických xxxxxxx, xxxx. d- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/,

xxxxxxxxxx,

xxxxxxxxxxx,

xxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx (x-),

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxxx, 

x-xxxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx není xxxxxxxx xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.

(x) Specifická xxxxxxxxxxx.

Xxxxxxxx (ale xx x xxxxxxxx pouze xx ně):

Adrenalin (xxxxxxxxx)****,

xxxxxxxxxxx,

xxxxxxxxxxxxxxxxx,

xxxxxxx***,

xxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx x xxxx deriváty,

fenkamfamin,

fenmetrazin,

fenprometamin,

heptaminol,

hydroxyamfetamin (xxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxx,

xxxxx**,

xxxxxxx x xxxx xxxxxxx (např. xxxxxxxx, xxxxxxxxx a xxxx-xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxxxx***,

xxxxxxxxxxxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx),

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxx (xxxxxxxxxxxxx),

xxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxxx,

xxxxxxxxxxxxx*****,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx/xxxxxx použití x xxxxxxxxxxx zahrnutých do Xxxxxxxxxxxxxx programu xxx xxx 2017*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2017 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: je xxxxxxxx xxxxx při koncentraci xxxxx xxx 5 xxxxxxxxxx v 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx: jsou xxxxxxxx xxx koncentraci xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Adrenalin (xxxxxxxxx): xxxx zakázán xxx xxxxxxxx xxxxxx, xxxx. xxxxx, oční xxxxxxxx xxxx xxxx xxxxxx xxxxxxxx s xxxxxxxxx anestetiky.

***** Pseudoefedrin: xx xxxxxxx, xxxxx xxxx koncentrace x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx mililitr.

S7. XXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

Xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx(xxxxxx),

xxxxxxxx x xxxx deriváty,

hydromorfon,

metadon,

morfin,

nikomorfin,

oxykodon,

oxymorfon,

pentazocin,

petidin.

S8. XXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

• Xxxxxxxx (např. xxxxx, xxxxxx x xxxxxxxxx) xxxx syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (THC).

• Kanabimimetika, xxxx. "Xxxxx", XXX018, XXX073 x XX-210.

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx podávané orálně, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.

XXXXX XXXXXXXX V URČITÝCH XXXXXXXX

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Soutěži v xxxxxxxxxxxxx sportech. Xxxxxxx xx bude provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Prahová xxxxxxx xxx porušení xxxxxxxxxxx xxxxxxxx je xxxxxxxxxxxx koncentraci xxxxxxxx x krvi 0,10 x/x.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxxxxx (XX)

• Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x xxx xx to xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (všechny xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxxx sporty (xxxxxxxxx xxxxxxxx) (XXXX) x disciplínách konstantní xxxx x xxxxxxxxx xxxx xxx ploutví, xxxxxxxxx apnoe x xxxxxxxxx xxxx bez xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, spearfishing, xxxxxxxx apnoe, xxxxxxx xxxxxxxx xx xxxx x xxxxxxxxxx váha.

• Střelba (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxx, 

xxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxxx,

xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx předpis č. 80/2017 Sb. x. x. xxxxx xxxxxxxxx xxxx 4.1.2018.

Xxxxxx předpis x. 80/2017 Xx. x. x. xxx xxxxxx právním xxxxxxxxx č. 36/2019 Sb. m. s. x účinností xx 26.7.2019.

Znění jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx aktualizováno, xxxxx se xxxx xxxxxx xxxxxxxxx změna xxxxx uvedeného xxxxxxxx xxxxxxxx.

1) Mezinárodní xxxxxx xxxxx dopingu ve xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx v xxxxxxxxx xxxxx x x xxxxxxxxx xx xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Úmluvy xx xxxxxxx jazyka xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.